Amfonelic Acid
Amfonelic acid is a potent, selective dopamine reuptake inhibitor originally investigated as an antibacterial and later as a research stimulant. It has strong preclinical dopaminergic activity but essentially no human clinical development; it circulates only as a research chemical.
01 Overview
Amfonelic acid is a quinoline carboxylic acid with unusually selective and long-lasting dopamine reuptake inhibition, widely used as a pharmacological tool in animal studies of dopamine function.
It was never developed as a human medicine and has no approved use, no clinical dosing and no human safety data. Its high potency and long action make untested human use hazardous; it exists in the grey market purely as an RC/tool compound.
02 Mechanism
Highly selective and potent dopamine reuptake inhibitor at the dopamine transporter, with long duration, producing strong dopaminergic stimulation in preclinical models.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| No validated dose | 0 mg | Oral | No established human dosing; potent and long-acting — untested. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Dopaminergic stimulationStrong locomotor stimulation and wakefulness in animal models via selective DAT inhibition. | n/a | Preclinical | |
| Cognitive/alerting effectSparse anecdotal reports of intense, long stimulation in humans; no controlled data. | n/a | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Overstimulation / insomniaProlonged wakefulness, agitation and marked insomnia due to long duration. | Moderate | Reported | Anecdotal | |
| Unknown toxicityNo human safety data; potent dopaminergic action raises psychosis and cardiovascular concerns. | Severe | Uncharacterised | Unconfirmed |